Ad-SGE-DKK3 gene therapy - Kyorin

Drug Profile

Ad-SGE-DKK3 gene therapy - Kyorin

Alternative Names: Ad-SGE-DKK-3 gene therapy - Kyorin; Ad-SGE-DKK3/REIC gene therapy - Kyorin; Ad-SGE-REIC gene therapy - Kyorin; Ad-SGE-REIC/Dkk-3 gene therapy - Kyorin; Ad-SGE-REIC/DKK3 gene therapy - Kyorin; Adenovirus super gene expression DKK3 gene therapy - Kyorin; Dickkopf3/reduced expression in immortalised cells gene therapy - Kyorin; Dkk-3 gene therapy - Kyorin; Dkk-3/REIC gene therapy - Kyorin; DKK3 gene therapy - Kyorin; DKK3/REIC gene therapy - Kyorin; Malignant pleural mesothelioma gene therapy - Kyorin; Reduced expression in immortalised cells/Dickkopf-3 gene therapy - Kyorin; REIC gene therapy - Kyorin; REIC/DKK3 gene therapy - Kyorin

Latest Information Update: 10 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Kyorin Pharmaceutical; Momotaro-Gene; Okayama University
  • Class Gene therapies
  • Mechanism of Action Apoptosis stimulants; DKK3 expression modulators; Gene transference; Immunostimulants; Tumour suppressor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mesothelioma

Most Recent Events

  • 29 Jul 2016 Ad-SGE-DKK3 gene therapy is still in phase I/II trials for Mesothelioma (malignant pleural) in Japan (Kyorin Holdings Investor Information, July 2016)
  • 01 May 2014 Phase-I/II clinical trials in Mesothelioma in Japan (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top